Iranian Red Crescent Medical Journal

Published by: Kowsar

How Should We Manage Latent Tuberculosis Infection in Patients Receiving Anti-TNF-α Drugs: Literature Review

Hamid Reza Naderi 1 , * , Fereshte Sheybani 1 and Susan Rezaei Pajand 1
Authors Information
1 Faculty of Medicine, Department of Infectious Diseases, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: December 01, 2016, 18 (12); e27756
  • Published Online: August 30, 2016
  • Article Type: Review Article
  • Received: February 8, 2015
  • Revised: March 30, 2015
  • Accepted: April 19, 2015
  • DOI: 10.5812/ircmj.27756

To Cite: Naderi H R, Sheybani F, Rezaei Pajand S. How Should We Manage Latent Tuberculosis Infection in Patients Receiving Anti-TNF-α Drugs: Literature Review, Iran Red Crescent Med J. 2016 ; 18(12):e27756. doi: 10.5812/ircmj.27756.

Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Global tuberculosis report 2013. 2013;
  • 2. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011; 378(9785): 57-72[DOI][PubMed]
  • 3. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013; 368(8): 745-55[DOI][PubMed]
  • 4. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000; 161(4 Pt 2)-47[DOI][PubMed]
  • 5. Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, DellaLatta P, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med. 2002; 346(19): 1453-8[DOI][PubMed]
  • 6. Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest. 2012; 142(3): 761-73[DOI][PubMed]
  • 7. Hauck FR, Neese BH, Panchal AS, El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician. 2009; 79(10): 879-86[PubMed]
  • 8. Horsburgh CR, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011; 364(15): 1441-8[DOI][PubMed]
  • 9. Schwartzman K. Latent tuberculosis infection: old problem, new priorities. CMAJ. 2002; 166(6): 759-61[PubMed]
  • 10. Kwon M, Sung M, Kwon YJ, Song YG, Lee SW, Park MC, et al. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis. J Clin Rheumatol. 2014; 20(2): 68-73[DOI][PubMed]
  • 11. Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, et al. The use of TNF-alpha blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol. 2014; 33(4): 543-7[DOI][PubMed]
  • 12. Newton SM, Mackie SL, Martineau AR, Wilkinson KA, Kampmann B, Fisher C, et al. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. Clin Vaccine Immunol. 2008; 15(3): 506-12[DOI][PubMed]
  • 13. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, Kirschner DE, et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun. 2008; 76(3): 916-26[DOI][PubMed]
  • 14. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis. 2005; 41 Suppl 3-93[DOI][PubMed]
  • 15. Kindler V, Sappino AP. The beneficial effects of localized tumor necrosis factor production in BCG infection. Behring Inst Mitt. 1991; (88): 120-4[PubMed]
  • 16. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15): 1098-104[DOI][PubMed]
  • 17. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Biobadaser Group . Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48(8): 2122-7[DOI][PubMed]
  • 18. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50(2): 372-9[DOI][PubMed]
  • 19. Nalbant S, Ozyurt M, Yildirim M, Kuskucu M. Pulmonary tuberculosis and tuberculous arthritis of knee joint associated with rheumatoid arthritis treated with anti-tumor necrosis factor (TNF)-alpha medication: a case report. Rheumatol Int. 2012; 32(9): 2863-6[DOI][PubMed]
  • 20. Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012; 59(7): 4480[PubMed]
  • 21. S Wallis R. tumor necrosis factor alpha inhibitors and mycobacterial infections. 2015;
  • 22. Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity rev. 2015; 14(6): 503-9
  • 23. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006; 10(10): 1127-32[PubMed]
  • 24. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004; 350(20): 2060-7[DOI][PubMed]
  • 25. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004; 4(12): 761-76[DOI][PubMed]
  • 26. Madariaga MG, Jalali Z, Swindells S. Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med. 2007; 20(6): 540-7[DOI][PubMed]
  • 27. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. 2000; 49: 1-51
  • 28. CDC. . Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004; 53(30): 683-6[PubMed]
  • 29. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006; 54(4): 1075-86[DOI][PubMed]
  • 30. Piana F, Codecasa LR, Cavallerio P, Ferrarese M, Migliori GB, Barbarano L, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J. 2006; 28(1): 31-4[DOI][PubMed]
  • 31. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res. 2006; 7: 56[DOI][PubMed]
  • 32. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J. 2006; 28(1): 24-30[DOI][PubMed]
  • 33. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2006; 174(7): 736-42[DOI][PubMed]
  • 34. Shim TS. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy. Intest Res. 2014; 12(1): 12-9[DOI][PubMed]
  • 35. Kim HC, Jo KW, Jung YJ, Yoo B, Lee CK, Kim YG, et al. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay. Scand J Infect Dis. 2014; 46(11): 763-9[DOI][PubMed]
  • 36. Piana F, Codecasa LR, Besozzi G, Migliori GB, Cirillo DM. Use of commercial interferon-gamma assays in immunocompromised patients for tuberculosis diagnosis. Am J Respir Crit Care Med. 2006; 173(1): 130[DOI][PubMed]
  • 37. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J. 2006; 28(1): 45-50[DOI][PubMed]
  • 38. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest. 2007; 131(5): 1424-34[DOI][PubMed]
  • 39. Tin SS, Wiwanitkit V. QuantiFERON-TB gold in-tube test vs. tuberculin skin test. Tuberk Toraks. 2014; 62(4): 324[PubMed]
  • 40. Kurt OK, Kurt B, Talay F, Tug T, Soy M, Bes C, et al. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis. Wien Klin Wochenschr. 2013; 125(19-20): 616-20[DOI][PubMed]
  • 41. Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol. 2008; 27(9): 1083-6[DOI][PubMed]
  • 42. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J. 2009; 33(3): 586-93[DOI][PubMed]
  • 43. Munoz L, Casas S, Juanola X, Bordas X, Martinez C, Santin M, et al. Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study. Clin Infect Dis. 2015; 60(3): 349-56[DOI][PubMed]
  • 44. Shim TS. Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy. Tuberc Respir Dis (Seoul). 2014; 76(6): 261-8[DOI][PubMed]
  • 45. Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int. 2012; 32(9): 2675-9[DOI][PubMed]
  • 46. Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, et al. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2010; 30(11): 1459-63[DOI][PubMed]
  • 47. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum. 2008; 59(6): 800-6[DOI][PubMed]
  • 48. Bonfiglioli KR, Ribeiro AC, Moraes JC, Saad CG, Souza FH, Calich AL, et al. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area. Int J Tuberc Lung Dis. 2014; 18(8): 905-11[DOI][PubMed]
  • 49. Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis. 2015; 74(10): 1848-53
  • 50. Assari R, Ziaee V, Ahmadinejad Z, Vasei M, Moradinejad MH. Caseous granuloma: tuberculosis or chronic recurrent multifocal osteomyelitis? Iran J Pediatr. 2014; 24(6): 770-4[PubMed]
  • 51. Gholoobi A, Masoudi-Kazemabad A, Meshkat M, Meshkat Z. Comparison of Culture and PCR Methods for Diagnosis of Mycobacterium tuberculosis in Different Clinical Specimens. Jundishapur J Microbiol. 2014; 7(2): 8939[DOI][PubMed]
  • 52. Heydari AA, Movahhede Danesh MR, Ghazvini K. Urine PCR evaluation to diagnose pulmonary tuberculosis. Jundishapur J Microbiol. 2014; 7(3): 9311[DOI][PubMed]
  • 53. Ebrahimzadeh A, Mohammadifard M, Naseh G. Comparison of chest x-ray findings of smear positive and smear negative patients with pulmonary tuberculosis. Iran J Radiol. 2014; 11(4): 13575[DOI][PubMed]
  • 54. Demir S, Sadi Aykan F, Oztuna D. [Latent tuberculosis treatment results in patients that taken TNF-alpha blockers at Ankara Numune Training and Research Hospital Chest Diseases Clinic for last 8 years (2006-2013)]. Tuberk Toraks. 2014; 62(4): 286-90[PubMed]
  • 55. Balbir-Gurman A, Lidgi M, Elkayam O. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers]. Harefuah. 2014; 153(6): 359-61[PubMed]
  • 56. Valls V, Ena J. Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy. Clin Rheumatol. 2015; 34(1): 29-34[DOI][PubMed]
  • 57. Treatment of Tuberculosis. Morb Mortal Wkly Rep. 2003; 52
  • 58. Yoshikawa K, Sato F, Hiroshi Takeda H, Masaki Yoshida M, Akira Kojima A, Seiji Hori S. Three cases of active tuberculosis in patients receiving anti-TNF (tumor necrosis factor) agents despite treatment for latent tuberculosis infection. Jpn J Chemother. 2014; : 681-6
  • 59. Alavi SM, Alavi L. Review on Epidemiology, Diagnosis, Occupational Hazards and Management of Pulmonary Tuberculosis in Elderly: A Guide for General Physicians Working in the Health Network Setting, Khuzestan, Iran. Jundishapur J Microbiol. 2013; 6(5)
  • 60. Byun JM, Lee CK, Rhee SY, Kim HJ, Kim JW, Shim JJ, et al. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-alpha blockers. J Korean Med Sci. 2015; 30(2): 173-9[DOI][PubMed]
  • 61. Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci. 2007; 22(5): 779-83[DOI][PubMed]
  • 62. Hanta I, Ozbek S, Kuleci S, Seydaoglu G, Ozyilmaz E. Detection of latent tuberculosis infection in rheumatologic diseases before anti-TNFalpha therapy: tuberculin skin test versus IFN-gamma assay. Rheumatol Int. 2012; 32(11): 3599-603[DOI][PubMed]
  • 63. Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, et al. Serial QuantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatment. J Infect. 2013; 66(4): 346-56[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments